Ftse Mib
34.300,17
-0,22%
DAX
18.504,68
-0,51%
S&P 500
5.631,22
0,00%
NASDAQ
18.472,57
0,00%
Bitcoin
63.798,26
-1,62%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Blueprint Medicines Corporation (BPMC) Blueprint Medicines Corporation (BPMC) Notizie

BPMC

Blueprint Medicines (BPMC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC
DataOraFonteTitoloSimboloCompagnia
24/02/202022:05PR Newswire (US)Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mast...NASDAQ:BPMCBlueprint Medicines Corporation
19/02/202014:00PR Newswire (US)Blueprint Medicines to Present at Upcoming Investor ConferencesNASDAQ:BPMCBlueprint Medicines Corporation
18/02/202022:56Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BPMCBlueprint Medicines Corporation
14/02/202019:50Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BPMCBlueprint Medicines Corporation
13/02/202023:33Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:BPMCBlueprint Medicines Corporation
13/02/202023:12Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BPMCBlueprint Medicines Corporation
13/02/202022:41Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BPMCBlueprint Medicines Corporation
13/02/202013:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BPMCBlueprint Medicines Corporation
13/02/202013:00PR Newswire (US)Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
06/02/202022:05PR Newswire (US)Blueprint Medicines to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020NASDAQ:BPMCBlueprint Medicines Corporation
06/02/202014:00PR Newswire (US)Blueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with F...NASDAQ:BPMCBlueprint Medicines Corporation
28/01/202017:50Edgar (US Regulatory)Schedule 13gNASDAQ:BPMCBlueprint Medicines Corporation
23/01/202022:24Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:BPMCBlueprint Medicines Corporation
23/01/202004:24PR Newswire (US)Blueprint Medicines Announces Pricing of Public Offering of Shares of Common StockNASDAQ:BPMCBlueprint Medicines Corporation
21/01/202022:01PR Newswire (US)Blueprint Medicines Announces Proposed Public Offering of Shares of Common StockNASDAQ:BPMCBlueprint Medicines Corporation
13/01/202014:00PR Newswire (US)Blueprint Medicines Announces 2020 Corporate GoalsNASDAQ:BPMCBlueprint Medicines Corporation
09/01/202022:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BPMCBlueprint Medicines Corporation
09/01/202021:52PR Newswire (US)Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metas...NASDAQ:BPMCBlueprint Medicines Corporation
08/01/202014:00PR Newswire (US)Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of ...NASDAQ:BPMCBlueprint Medicines Corporation
06/01/202014:00PR Newswire (US)CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 f...NASDAQ:BPMCBlueprint Medicines Corporation
08/12/201915:00PR Newswire (US)Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Masto...NASDAQ:BPMCBlueprint Medicines Corporation
14/11/201914:00PR Newswire (US)Blueprint Medicines to Present at Jefferies 2019 London Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
06/11/201915:00PR Newswire (US)Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mast...NASDAQ:BPMCBlueprint Medicines Corporation
05/11/201913:40Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BPMCBlueprint Medicines Corporation
05/11/201913:00PR Newswire (US)Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at ...NASDAQ:BPMCBlueprint Medicines Corporation
29/10/201913:00PR Newswire (US)Blueprint Medicines to Host R&D Day and Announce Third Quarter 2019 Financial Results on November 5, 2019NASDAQ:BPMCBlueprint Medicines Corporation
28/10/201913:00PR Newswire (US)Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon ...NASDAQ:BPMCBlueprint Medicines Corporation
27/09/201919:06Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:BPMCBlueprint Medicines Corporation
28/08/201914:00PR Newswire (US)Blueprint Medicines to Present at Upcoming Investor Conferences in SeptemberNASDAQ:BPMCBlueprint Medicines Corporation
07/08/201914:00PR Newswire (US)Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Muta...NASDAQ:BPMCBlueprint Medicines Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC

La tua Cronologia

BIT
1GME
Gamestop
LSE
LWI
Lowland Investment
LSE
CBU3
Ishr $ Gov 1-3a
NASDAQ
CRNX
Crinetics Pharmaceuticals
NASDAQ
FARO
FARO Technologies
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network